F10 and hemophilia A: Currently, there are two FDA approved bispecific antibodies for clinical use: blinatumomab, used to treat acute hematological malignancies via CD3 and CD19, and emicizumab, which binds the coagulation factor IX and factor X for treatment of hemophilia A [37].